Pipes Feed Preview: ClinicalTrials.gov: COVID-19 | Last update posted in the last 14 days

  1. Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus

    Wed, 18 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID - 19; SARS CoV-2 <br/><b>Interventions</b>: Biological: COVID-19 Vaccines; Biological: COVID-19 Vaccines <br/><b>Sponsors</b>: Rokote Laboratories Finland Oy; Oy Medfiles Ltd; Estimates OY <br/><b>Recruiting</b>

  2. Persistent COVID-19 Registry in Navarre.

    Wed, 18 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Long COVID Symptoms; Long COVI <br/><b>Sponsors</b>: Fundacion Miguel Servet <br/><b>Recruiting</b>

  3. A Fasting Pilot Study for Long COVID

    Wed, 18 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Long COVID Syndrome <br/><b>Interventions</b>: Other: prolonged fasting <br/><b>Sponsors</b>: Université de Sherbrooke; Centre de recherche du CHU de Sherbrooke <br/><b>Completed</b>

  4. Vitamin E Supplementation As Adjunctive Therapy To Lower Inflammation In COVID-19 Patients

    Tue, 17 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID - 19 <br/><b>Interventions</b>: Drug: Patients were randomly assigned, under a double-blind design, α-Tocopherol group (n = 22) <br/><b>Sponsors</b>: Universidad Veracruzana <br/><b>Completed</b>

  5. Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda

    Fri, 13 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID -19; SARS CoV 2 Infection <br/><b>Interventions</b>: Biological: Janssen Ad26COVS1; Biological: Pfizer-BioNTech vaccine COVID-19 vaccine; Biological: Inactivated Sinopharm or Sinovac COVID-19 vaccine <br/><b>Sponsors</b>: Victoria Biomedical Research Institute; Rinda Ubuzima, Rwanda; University of Kinshasa; Coalition for Epidemic Preparedness Innovations <br/><b>Completed</b>

  6. Pathophysiology of Dysautonomia and Postural Tachycardia Syndrome (POTS) in Post-viral Syndromes and COVID-19

    Thu, 12 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: POTS; POTS - Postural Orthostatic Tachycardia Syndrome; Dysautonomia; Autonomic Dysfunction <br/><b>Interventions</b>: Other: Blood Sample Collection <br/><b>Sponsors</b>: Brigham and Women's Hospital; FBRI LLC (F-Prime Capital) <br/><b>Active, not recruiting</b>

  7. OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients

    Wed, 18 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19; Immunodeficiency <br/><b>Interventions</b>: Drug: Paxlovid 5 days; Drug: Paxlovid 10 days <br/><b>Sponsors</b>: Calmy Alexandra; ANRS, Emerging Infectious Diseases <br/><b>Recruiting</b>

  8. Clinical Laboratory Evaluation, Assessment of Symptoms and Recovery in Patients With Post-COVID-19-Vaccination Syndrome

    Tue, 10 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Post-Acute COVID-19 Vaccination Syndrome; Postviral Fatigue <br/><b>Interventions</b>: Diagnostic Test: Blood sampling and analysis; Other: The continuous Reactive Hyperemia Index (InRHI) measured by EndoPAT <br/><b>Sponsors</b>: University of Bern; private practice Cell-Re-Active-Training in Bern; Post-Vakzin-Syndrom Schweiz; Medical University Innsbruck <br/><b>Recruiting</b>

  9. Usability and Clinical Validation of the NowFuture Digital Flu / COVID Test in Anterior Nasal Samples for Over-the-counter (OTC) Use

    Wed, 11 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: SARS CoV 2 Infection; Influenza A Virus Infection; Influenza B Virus Infection <br/><b>Interventions</b>: Diagnostic Test: Diagnostic test for SARS-CoV-2, influenza A and influenza B <br/><b>Sponsors</b>: Biocrucible Ltd <br/><b>Not yet recruiting</b>

  10. Long-Term Outcomes After ICU-Treated COVID-19 ARDS

    Mon, 09 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19; ARDS (Acute Respiratory Distress Syndrome) <br/><b>Sponsors</b>: University in Zielona Góra <br/><b>Completed</b>

  11. Clinical Trial on a Natural Compound to Improve Chronic Inflammation After SARS-CoV-2 Infection

    Mon, 09 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Long COVID <br/><b>Interventions</b>: Dietary Supplement: Experimental Product; Dietary Supplement: Control placebo; Other: Physical exercise; Other: No Physical Exercise <br/><b>Sponsors</b>: Universidad Católica San Antonio de Murcia <br/><b>Not yet recruiting</b>

  12. Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants

    Mon, 09 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: SARS-CoV-2 (COVID-19) <br/><b>Interventions</b>: Biological: SARS-CoV-2 Omicron EG.5.1 challenge agent 10^5 TCID50; Biological: SARS-CoV-2 Omicron EG.5.1 challenge agent 10^6 TCID50; Biological: SARS-CoV-2 Omicron EG.5.1 challenge agent 10^4 TCID50 <br/><b>Sponsors</b>: Imperial College London <br/><b>Not yet recruiting</b>

  13. Inspiratory Muscle Pressure and Diaphragmatic Strength in Women With Long COVID-19: A Pressure Biofeedback-Guided Training Study

    Mon, 09 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Long COVID-19 Syndrome; Post COVID Syndrome Long Covid; Post COVID-19 Syndrome <br/><b>Interventions</b>: Device: Pressure Biofeedback Unit <br/><b>Sponsors</b>: RSUP Persahabatan <br/><b>Completed</b>

  14. Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients

    Mon, 09 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Hematopoietic and Lymphatic System Neoplasm <br/><b>Interventions</b>: Biological: SARS-CoV-2 mRNA Vaccine ARCT-021; Biological: Tozinameran; Procedure: Biospecimen Collection; Other: Electronic Health Record Review; Other: Survey Administration <br/><b>Sponsors</b>: Fred Hutchinson Cancer Center; Arcturus Therapeutics, Inc.; Seqirus <br/><b>Not yet recruiting</b>

  15. Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

    Wed, 18 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Post-Acute COVID-19 Syndrome <br/><b>Interventions</b>: Drug: Keytruda <br/><b>Sponsors</b>: National Institute of Neurological Disorders and Stroke (NINDS) <br/><b>Not yet recruiting</b>

  16. Study SARS-CoV-2-CZ-PREVAL-II - Arm of the Olomouc Region

    Wed, 04 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: SARS-CoV-2; SARS-CoV-2 (COVID-19) Infection <br/><b>Interventions</b>: Procedure: Blood sampling; Procedure: Gargle sampling; Other: Questionnaire completion; Diagnostic Test: Body temperature measurement <br/><b>Sponsors</b>: The Institute of Molecular and Translational Medicine, Czech Republic; Palacky University; University Hospital Olomouc <br/><b>Completed</b>

  17. Stellate Ganglion Block for Long COVID Symptoms: A Randomized Controlled Trial

    Mon, 09 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Long COVID <br/><b>Interventions</b>: Procedure: Stellate Ganglion Block (Bupivacaine); Procedure: placebo saline injection <br/><b>Sponsors</b>: Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec <br/><b>Recruiting</b>

  18. Sonlicromanol in Post-COVID

    Fri, 06 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Post COVID Condition <br/><b>Interventions</b>: Drug: Sonlicromanol; Drug: Placebo <br/><b>Sponsors</b>: Michele van Vugt; ZonMw: The Netherlands Organisation for Health Research and Development; Khondrion BV <br/><b>Not yet recruiting</b>

  19. A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

    Wed, 11 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19; SARS-COV-2 Infection <br/><b>Interventions</b>: Biological: BNT162b2 (2025/2026 formulation) <br/><b>Sponsors</b>: BioNTech SE; Pfizer <br/><b>Active, not recruiting</b>

  20. A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

    Fri, 13 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Drug: Aluminum Hydroxide Suspension; Biological: Boost-2867; Biological: CpG 7909; Other: Sodium Chloride, 0.9% <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Recruiting</b>

  21. Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults

    Tue, 17 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Biological: PepGNP-COVID19; Other: Sterile Water for Injection <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Recruiting</b>

  22. Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

    Wed, 18 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Respiratory Tract Infection; Smell Disorder; Influenza; Rhinosinusitis; COVID-19; Depression; Parosmia; Hyposomia; Normosomia; Anosmia <br/><b>Sponsors</b>: National Institute on Deafness and Other Communication Disorders (NIDCD) <br/><b>Not yet recruiting</b>

  23. Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults

    Fri, 06 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Biological: STX-S <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Active, not recruiting</b>

  24. Safety and Immunogenicity of NVX-CoV2705

    Fri, 13 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19; SARS-CoV-2 Infection <br/><b>Interventions</b>: Biological: NVX-CoV2705 <br/><b>Sponsors</b>: Sanofi; Novavax <br/><b>Active, not recruiting</b>

  25. A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

    Mon, 09 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 (Coronavirus Disease 2019) <br/><b>Interventions</b>: Drug: nirmatrelvir-ritonavir <br/><b>Sponsors</b>: Pfizer <br/><b>Completed</b>

  26. A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

    Wed, 04 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection <br/><b>Interventions</b>: Drug: ibuzatrelvir; Drug: remdesivir; Drug: placebo for ibuzatrelvir; Drug: placebo for remdesivir <br/><b>Sponsors</b>: Pfizer <br/><b>Recruiting</b>

  27. Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project

    Wed, 11 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Long COVID-19; Acute COVID-19; Postural Orthostatic Tachycardia Syndrome (POTS); Diabetic Neuropathy <br/><b>Sponsors</b>: CND Life Sciences <br/><b>Recruiting</b>

  28. Cognitive-Sensorimotor Function in Long-COVID

    Tue, 10 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Post-acute Sequelae of SARS-CoV-2 Infection <br/><b>Sponsors</b>: VA Office of Research and Development; Edward Hines Jr. VA Hospital <br/><b>Not yet recruiting</b>

  29. Bern, Get Ready (BEready) Cohort Study for Pandemic Preparedness

    Thu, 05 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Pandemic, COVID-19; Infections; Zoonoses; Epidemic Disease; Respiratory Tract Infections <br/><b>Sponsors</b>: University of Bern; Stiftung Vinetum <br/><b>Active, not recruiting</b>

  30. A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

    Wed, 04 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 SARS-CoV-2 Infection <br/><b>Interventions</b>: Drug: ibuzatrelvir; Drug: placebo <br/><b>Sponsors</b>: Pfizer <br/><b>Recruiting</b>

  31. A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

    Thu, 12 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Coronavirus Disease (COVID-19) <br/><b>Interventions</b>: Drug: Molnupiravir; Drug: Placebo <br/><b>Sponsors</b>: Merck Sharp & Dohme LLC <br/><b>Recruiting</b>

  32. Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

    Wed, 18 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Long COVID; Sars-CoV-2 Infection; Coronavirus Infections; COVID-19 <br/><b>Interventions</b>: Drug: Baricitinib; Other: Placebo <br/><b>Sponsors</b>: Wes Ely; National Institutes of Health (NIH); National Institute on Aging (NIA) <br/><b>Recruiting</b>

  33. Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.

    Tue, 17 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Pneumonia, Community-Acquired; COVID-19 Pneumonia; Cardiovascular Diseases <br/><b>Interventions</b>: Other: Blood samples and Oropharyngeal swab; Other: Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms <br/><b>Sponsors</b>: Hellenic Institute for the Study of Sepsis <br/><b>Recruiting</b>

  34. Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

    Tue, 17 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: PASC Post Acute Sequelae of COVID-19 <br/><b>Sponsors</b>: National Institute of Neurological Disorders and Stroke (NINDS) <br/><b>Recruiting</b>

  35. Evaluating Social Perception Dynamics

    Fri, 13 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Mental Health Issue; COVID-19 <br/><b>Interventions</b>: Behavioral: Social perception tasks <br/><b>Sponsors</b>: Yale University; National Institute of Mental Health (NIMH) <br/><b>Enrolling by invitation</b>

  36. Drum Circle Synchrony Study 2c.a.

    Fri, 13 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Mental Health Issue; COVID-19 <br/><b>Interventions</b>: Behavioral: Communal drumming recordings <br/><b>Sponsors</b>: Yale University; National Institute of Mental Health (NIMH) <br/><b>Enrolling by invitation</b>

  37. Evaluating the Community Drum Circle

    Thu, 12 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Mental Health Issue; COVID-19 <br/><b>Interventions</b>: Behavioral: Communal Drumming; Behavioral: Communal drumming recordings <br/><b>Sponsors</b>: Yale University; National Institute of Mental Health (NIMH) <br/><b>Enrolling by invitation</b>

  38. Evaluating the Impact of Social Music

    Thu, 12 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Mental Health Issue; COVID-19 <br/><b>Interventions</b>: Behavioral: Music <br/><b>Sponsors</b>: Yale University; National Institute of Mental Health (NIMH) <br/><b>Recruiting</b>

  39. Music Mindfulness Study 2a.

    Thu, 12 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Mental Health Issue; COVID-19 <br/><b>Interventions</b>: Behavioral: in person meditation; Behavioral: in person meditation using headphones; Behavioral: virtual meditation <br/><b>Sponsors</b>: Yale University; National Institute of Mental Health (NIMH) <br/><b>Recruiting</b>

  40. Balance Acceptance and Commitment Therapy for Long COVID

    Wed, 11 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Post-COVID-19 Syndrome; Long COVID <br/><b>Interventions</b>: Behavioral: Balance Acceptance and Commitment Therapy <br/><b>Sponsors</b>: King's College London <br/><b>Active, not recruiting</b>

  41. Exercise Training Using an App on Physical Cardiovascular Function Individuals With Post-covid-19 Syndrome

    Tue, 17 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Post-Acute COVID-19 Syndrome <br/><b>Interventions</b>: Behavioral: Exercise; Behavioral: Control <br/><b>Sponsors</b>: University of Nove de Julho <br/><b>Recruiting</b>

  42. Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)

    Tue, 10 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19, SARS-CoV-2 Infection; RSV; Influenza <br/><b>Sponsors</b>: VA Office of Research and Development; Biomedical Advanced Research and Development Authority; Food and Drug Administration (FDA) <br/><b>Recruiting</b>

  43. Presynaptic Imaging in Major Depressive Episodes After COVID-19

    Wed, 11 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Long COVID; Major Depressive Disorder; Major Depressive Episode <br/><b>Interventions</b>: Other: [11C]DTBZ PET scan; Other: [18F]SDM8 PET scan; Other: MRI scan <br/><b>Sponsors</b>: Centre for Addiction and Mental Health <br/><b>Recruiting</b>

  44. Mind Body Intervention for Long COVID-19

    Wed, 18 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Long COVID; Post-Acute Sequelae of COVID-19; COVID Long-Haul <br/><b>Interventions</b>: Behavioral: Mind Body Intervention #1 <br/><b>Sponsors</b>: Beth Israel Deaconess Medical Center <br/><b>Recruiting</b>

  45. PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19

    Fri, 13 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: SARS-CoV-2 <br/><b>Interventions</b>: Drug: Upamostat; Drug: Placebo (PO) <br/><b>Sponsors</b>: Henry M. Jackson Foundation for the Advancement of Military Medicine; Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies; RedHill Biopharma Limited; FHI Clinical, Inc. <br/><b>Completed</b>

  46. Characterization of the Immunometabolic Signature in Long COVID-19.

    Tue, 10 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Long COVID <br/><b>Interventions</b>: Biological: Blood sample (at inclusion and 6 months later); Other: Patient questionnaires (at inclusion and 6 months later) <br/><b>Sponsors</b>: University Hospital, Angers <br/><b>Completed</b>

  47. Cognitive, Psychological, and Physical Functioning in Long-COVID Patients With Different Levels of Fatigue.

    Thu, 12 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Post-Acute COVID-19 Syndrome <br/><b>Sponsors</b>: Hasselt University <br/><b>Completed</b>

  48. Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction

    Thu, 12 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Anosmia; Hyposmia; Parosmia; Olfactory Disorder <br/><b>Interventions</b>: Drug: Stellate Ganglion Block <br/><b>Sponsors</b>: Washington University School of Medicine <br/><b>Completed</b>

  49. COVID-19 Experiences in the SELF Cohort

    Tue, 17 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Sponsors</b>: National Institute of Environmental Health Sciences (NIEHS) <br/><b>Enrolling by invitation</b>

  50. Correlation of Lung Ultrasonography With Chest CT Findings in Cancer Patients With COVID-19 Viral Pneumonia

    Wed, 18 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Cancer Patients <br/><b>Interventions</b>: Radiation: lung ultrasonography versus CT <br/><b>Sponsors</b>: South Egypt Cancer Institute <br/><b>Completed</b>

  51. 'Long COVID-19' in Suffolk and North Essex: Defining the Disease and Optimising Outcomes

    Fri, 06 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Covid19 <br/><b>Sponsors</b>: East Suffolk and North Essex NHS Foundation Trust <br/><b>Completed</b>

  52. Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

    Thu, 05 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Papillomavirus Infections; Coronavirus Disease (COVID-19) <br/><b>Interventions</b>: Biological: 9vHPV Vaccine; Biological: mRNA-1273 Vaccine <br/><b>Sponsors</b>: Merck Sharp & Dohme LLC <br/><b>Completed</b>

  53. Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19

    Thu, 05 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Sponsors</b>: National Cancer Institute (NCI) <br/><b>Completed</b>

  54. The Impact of COVID-19 on Pulmonary Procedures

    Fri, 13 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm <br/><b>Interventions</b>: Other: Survey Administration <br/><b>Sponsors</b>: M.D. Anderson Cancer Center <br/><b>Recruiting</b>

  55. SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

    Wed, 11 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia; Lymphoma; Plasma Cell Myeloma <br/><b>Interventions</b>: Biological: COVID-19 Vaccine; Other: Diagnostic Laboratory Biomarker Analysis; Biological: Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1 <br/><b>Sponsors</b>: GeoVax, Inc. <br/><b>Active, not recruiting</b>

  56. SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Testing Among Utah Community Health Centers

    Wed, 04 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Covid19 <br/><b>Interventions</b>: Behavioral: Text-Messaging (TM); Behavioral: Patient Navigation (PN) <br/><b>Sponsors</b>: University of Utah; Association for Utah Community Health; Utah Department of Health; National Institutes of Health (NIH); National Center for Advancing Translational Sciences (NCATS) <br/><b>Completed</b>

  57. The Impact of the COVID-19 Pandemic on Eating Behavior and Weight Change

    Tue, 17 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19; Obesity <br/><b>Sponsors</b>: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) <br/><b>Completed</b>

  58. Assessing Testing Strategies for Safe Return to K-12 Schools in an Underserved Population

    Wed, 18 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Covid19 <br/><b>Interventions</b>: Other: Screening testing strategy; Other: No screening testing strategy <br/><b>Sponsors</b>: Washington University School of Medicine <br/><b>Completed</b>

  59. Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)

    Tue, 17 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Covid19; Severe Acute Respiratory Syndrome; SARS-CoV-2 Infection <br/><b>Interventions</b>: Biological: ABNCoV2 Vaccine <br/><b>Sponsors</b>: Radboud University Medical Center; European Union <br/><b>Completed</b>

  60. Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

    Tue, 10 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Covid19; SARS-CoV Infection; ARDS; ARDS, Human <br/><b>Interventions</b>: Drug: Instilled T3; Other: Placebo Therapy <br/><b>Sponsors</b>: University of Minnesota <br/><b>Withdrawn</b>

  61. Evaluation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen

    Fri, 06 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Corona Virus Infection <br/><b>Interventions</b>: Diagnostic Test: Serological testing for COVID-19 infection <br/><b>Sponsors</b>: University Hospital, Rouen <br/><b>Completed</b>

  62. A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection

    Tue, 10 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection <br/><b>Interventions</b>: Drug: Placebo Administration; Biological: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 <br/><b>Sponsors</b>: GeoVax, Inc. <br/><b>Completed</b>

  63. Health-Related Quality of Life of Patients With Asthma During the Pandemic of COVID-19

    Tue, 10 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Asthma Chronic; Bronchial Asthma <br/><b>Sponsors</b>: Cairo University <br/><b>Completed</b>

  64. Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

    Wed, 11 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection; COVID-19-Associated Acute Respiratory Distress Syndrome; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Symptomatic COVID-19 Infection Laboratory-Confirmed <br/><b>Interventions</b>: Other: Best Practice; Biological: Mesenchymal Stem Cell <br/><b>Sponsors</b>: M.D. Anderson Cancer Center; National Cancer Institute (NCI) <br/><b>Recruiting</b>

  65. SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival

    Mon, 09 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Covid19; Hypoxic Respiratory Failure <br/><b>Interventions</b>: Drug: Isoflurane Inhalant Product; Drug: Sevoflurane inhalant product <br/><b>Sponsors</b>: Sunnybrook Health Sciences Centre <br/><b>Active, not recruiting</b>

  66. A Longitudinal Study of COVID-19 Sequelae and Immunity

    Tue, 17 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Active, not recruiting</b>

  67. Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS

    Tue, 10 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Drug: Tocilizumab; Drug: Placebo <br/><b>Sponsors</b>: Queen's Medical Center <br/><b>Terminated</b>

  68. Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection

    Mon, 09 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Lung Cancer; COVID; Corona Virus Infection <br/><b>Interventions</b>: Diagnostic Test: IgG test <br/><b>Sponsors</b>: Fundación GECP <br/><b>Completed</b>

  69. Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons

    Thu, 05 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Acute and Long Term Effects of COVID-19 on Systemic Inflammation; Acute and Long Term Effects of COVID-19 on Lung Function; Acute and Long Term Effects of COVID-19 on Cardiac Function; Acute and Long Term Effects of COVID-19 on Kidney Function; Acute and Long Term Effects of COVID-19 on Brain Function <br/><b>Sponsors</b>: National Institutes of Health Clinical Center (CC) <br/><b>Completed</b>

  70. COVID-19 and Cancer Patients

    Tue, 17 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Cancer; Sars-CoV2 <br/><b>Sponsors</b>: Imperial College London <br/><b>Completed</b>

  71. Vitamin D Levels in SARS-CoV-2: Do Current Adequacy Thresholds Reflect Clinical Risk? Insights From a Large Turkish Cohort

    Thu, 05 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID; Vitamin D Deficiency <br/><b>Interventions</b>: Dietary Supplement: vitamin d <br/><b>Sponsors</b>: Bursa City Hospital <br/><b>Completed</b>

  72. NCI COVID-19 in Cancer Patients, NCCAPS Study

    Wed, 18 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection; Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm <br/><b>Interventions</b>: Procedure: Biospecimen Collection; Other: Data Collection; Other: Quality-of-Life Assessment; Other: Questionnaire Administration <br/><b>Sponsors</b>: National Cancer Institute (NCI) <br/><b>Active, not recruiting</b>

  73. Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19

    Fri, 06 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19; Cancer <br/><b>Interventions</b>: Other: Telehealth <br/><b>Sponsors</b>: Duke University; University of California, San Diego <br/><b>Enrolling by invitation</b>

  74. A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients

    Fri, 06 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Drug: Hydroxychloroquine <br/><b>Sponsors</b>: Queen's Medical Center <br/><b>Terminated</b>

  75. Reducing Hopelessness Through Improved Physical Activity in Adults With Heart Disease: With COVID-19 Considerations

    Fri, 13 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Ischemic Heart Disease; Hopelessness; Physical Activity; Motivation; Social Support; Covid19 <br/><b>Interventions</b>: Behavioral: Motivational social support from nurse; Behavioral: Motivational social support from nurse with additional support from significant other; Behavioral: Attention control <br/><b>Sponsors</b>: University of Illinois at Chicago; National Institute of Nursing Research (NINR) <br/><b>Completed</b>

  76. LearningRx Cognitive Training for Brain Injury

    Fri, 13 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Traumatic Brain Injury (TBI); Acquired Brain Injury; Post COVID-19 Cognitive Impairment <br/><b>Interventions</b>: Behavioral: LearningRx cognitive training <br/><b>Sponsors</b>: Gibson Institute of Cognitive Research; Louisiana State University Health Sciences Center Shreveport <br/><b>Active, not recruiting</b>

  77. Viral Infections in Healthy and Immunocompromised Hosts

    Tue, 17 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Anogenital Herpes; COVID-19; Herpes Labialis <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Recruiting</b>